Expertise in
2
conditions

Nomathemba C. Chandiwana

University Of Cape Town, 
Cape Town, WC, ZA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
University Of Cape Town, 
Cape Town, WC, ZA 

Overview

Nomathemba Chandiwana practices practicing medicine in Cape Town, South Africa.

Chandiwana is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses HIV/AIDS, Obesity, Severe Acute Respiratory Syndrome (SARS), and COVID-19.

They are actively involved in clinical research, co-authoring 46 peer reviewed articles and participating in 5 clinical trials.

Locations

University Of Cape Town, Cape Town, WC, South Africa
Other Locations
Johannesburg, GT, South Africa
South Africa

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 Treatment
AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 Treatment
Enrollment Status: Recruiting
Publish Date: January 14, 2026
Intervention Type: Drug
Study Drugs: Molnupiravir, Nitazoxanide, VIR-7832, VIR-7831
Study Phase: Phase 1/Phase 2
A Single Arm, Phase 3 Study, Exploring the Safety of Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV, a Pilot Switch Study Strategy in South Africa
A Single Arm, Phase 3 Study, Exploring the Safety of Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV, a Pilot Switch Study Strategy in South Africa
Enrollment Status: Completed
Publish Date: August 03, 2023
Intervention Type: Drug
Study Drug: Doravirine+Lamivudine+Tenofovir Disoproxil Fumarate
Study Phase: Phase 3
A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT)
A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT)
Enrollment Status: Completed
Publish Date: July 14, 2022
Intervention Type: Drug
Study Drug: DuACT
Study Phase: Phase 2
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF/DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers and Inner City Inhabitants at High Risk of Exposure to SARS-CoV-2
A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF/DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers and Inner City Inhabitants at High Risk of Exposure to SARS-CoV-2
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug
Study Drugs: Nitazoxanide, Sofosbuvir/Daclatasvir
Study Phase: Phase 2
View 4 Less Clinical Trials

46 Total Publications

Analogue insulin, GLP-1, and the WHO Model Essential Medicines List.
Analogue insulin, GLP-1, and the WHO Model Essential Medicines List.
Journal: The lancet. Diabetes & endocrinology
Published: February 03, 2026

Frequently Asked Questions about Nomathemba C. Chandiwana

Is Nomathemba C. Chandiwana a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Nomathemba C. Chandiwana is classified as an Advanced expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Nomathemba C. Chandiwana participate in research or clinical trials?

Yes. Nomathemba C. Chandiwana has published 46 articles and abstracts on conditions like HIV/AIDS. You can view a list of Nomathemba C. Chandiwana's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chandiwana's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile